TREAT WITH

FORESIGHT

If you could not make it to EURETINA. Find the latest updates here!

go to link

Strong and sustained vision gains, proactive dosing Q8 and beyond^2,3

nAMD

EURETINA guidelines DME drug of choice in patients with baseline BCVA <69 letters^4,a

DME

In the Casselholm study, EYLEA^® provided significantly reduced injection frequency by 24% vs. ranibizumab^5,b,c

RVO

Strong, rapid, and sustained visual gains over 48 weeks⁶

mCNV

Dosing

Proactive dosing options across indications¹

Learn more

Mechanism of action

Unique, multi-targeted trap mechanism^1,7

Learn more

NEW in nAMD!

After 3 monthly EYLEA loading doses and one injection at Week 16, treatment can continue with proactive Q8 dosing or proactive treat-and-extend (T&E) dosing beyond Q8^1,d